NorthSea Therapeutics: NorthSea Therapeutics B.V.: NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes

NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH expec...